Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

STATs in oncogenesis.

T Bowman1, R Garcia, J Turkson

  • 1Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida, FL 33612, USA.

Oncogene
|June 13, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.

Oncogene·2011
Same author

Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation.

The Journal of biological chemistry·2001
Same author

STAT proteins: novel molecular targets for cancer drug discovery.

Oncogene·2001
Same author

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.

The Journal of clinical investigation·2001
Same author

Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling.

Oncogene·2000
Same author

Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity.

The Journal of biological chemistry·2000
Same journal

SRD5A3-mediated aberrant N-glycosylation of SCARA5 promotes ferroptosis in lung adenocarcinoma.

Oncogene·2026
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
See all related articles

Signal Transducers and Activators of Transcription (STATs) are crucial in cytokine signaling and cancer development. Aberrant STAT activation contributes to oncogenesis by promoting cell proliferation and preventing apoptosis, offering potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Oncology

Background:

  • Signal Transducers and Activators of Transcription (STATs) mediate cytokine signaling.
  • STATs play critical roles in normal cellular functions.
  • Oncoproteins can activate STATs, linking them to cancer.

Purpose of the Study:

  • To review the evidence for STATs' roles in oncogenesis.
  • To discuss the potential of STAT signaling as a therapeutic target in cancer.

Main Methods:

  • Review of existing literature on STATs in cancer.
  • Analysis of studies on STAT activation in tumors and cell lines.
  • Identification of STAT-regulated genes involved in oncogenesis.

Main Results:

Related Experiment Videos

  • Aberrant STAT activation is frequent in human cancers.
  • Activated STAT signaling contributes to malignant transformation.
  • STATs promote oncogenesis by stimulating proliferation and inhibiting apoptosis.

Conclusions:

  • STATs are critical mediators in oncogenesis.
  • Targeting STAT signaling pathways may lead to novel cancer therapies.